New drug duo tested in fight against tough lung cancers
NCT ID NCT06083857
Summary
This early-stage study is testing whether combining two targeted drugs, amivantamab and tepotinib, can help control advanced non-small cell lung cancer that has specific changes in a gene called MET. The main goals are to find a safe dose for the combination and to get an early look at whether it shrinks tumors. The study is for adults whose cancer has spread and is no longer responding to other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.